Genmab A/S

NasdaqGS:GMAB Stock Report

Market Cap: US$20.7b

Genmab Past Earnings Performance

Past criteria checks 6/6

Genmab has been growing earnings at an average annual rate of 15.9%, while the Biotechs industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 21.4% per year. Genmab's return on equity is 27.5%, and it has net margins of 41.2%.

Key information

15.93%

Earnings growth rate

16.71%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate21.40%
Return on equity27.53%
Net Margin41.17%
Next Earnings Update17 Feb 2026

Recent past performance updates

Recent updates

Genmab: AI Partnership And Clinical Data Fuel Growth

Jan 10

Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Mar 14

Genmab Is Too Attractive To Ignore

Dec 08

Genmab: Looking To Manage My Position Around Q3 Earnings

Nov 06

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Aug 23

Genmab: A Complicated Tale

May 01

Genmab Acquires A Missing Piece For Its Pipeline

Apr 16

Genmab: Recent Updates Support The Growth Narrative

Feb 21

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Jan 23

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Jan 12

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Oct 18

Genmab improves FY 2022 guidance

Aug 08

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Jul 19

Genmab: A Royalty Powerhouse With A Strong Pipeline

Jun 28

Revenue & Expenses Breakdown

How Genmab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:GMAB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 253,8461,5836431,567
30 Jun 253,6471,3716241,550
31 Mar 253,2311,1405501,425
31 Dec 242,9901,0905261,343
30 Sep 242,9647025191,349
30 Jun 242,7437985011,276
31 Mar 242,5767915041,187
31 Dec 232,4406454881,130
30 Sep 232,3895904661,033
30 Jun 232,378680453979
31 Mar 232,216757422890
31 Dec 222,088785385801
30 Sep 221,580745299688
30 Jun 221,438558268683
31 Mar 221,342354228667
31 Dec 211,288452196640
30 Sep 211,232448156590
30 Jun 211,168401134541
31 Mar 211,703880119512
31 Dec 201,660781108515
30 Sep 201,73688986453
30 Jun 201,55985373417
31 Mar 2083734956378
31 Dec 1980632551358
30 Sep 1953222342317
30 Jun 1948717839291
31 Mar 1944120236250
31 Dec 1846422633220
30 Sep 1843722230191
30 Jun 1839719428174
31 Mar 1846221326164
31 Dec 1738117824137
30 Sep 1736118421126
30 Jun 1735620819110
31 Mar 1727217416101
31 Dec 162571681494
30 Sep 162211111597
30 Jun 162051021490
31 Mar 16183821481
31 Dec 151651111371
30 Sep 15116661466
30 Jun 15115691466
31 Mar 15102601266

Quality Earnings: GMAB has high quality earnings.

Growing Profit Margin: GMAB's current net profit margins (41.2%) are higher than last year (23.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown by 15.9% per year over the past 5 years.

Accelerating Growth: GMAB's earnings growth over the past year (125.5%) exceeds its 5-year average (15.9% per year).

Earnings vs Industry: GMAB earnings growth over the past year (125.5%) exceeded the Biotechs industry 55.7%.

Return on Equity

High ROE: GMAB's Return on Equity (27.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/15 22:51
End of Day Share Price 2026/01/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James GordonBarclays
Xue ChenBarclays
Emily FieldBarclays